Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.

Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion. - Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006767

Enrollment

Registered

2011-11-30

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous non-small-cell lung cancer

Interventions

Carboplatin + Paclitaxel + Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed non-squamous non-small-cell lung cancer 2) Clinical stage IV or post-operative recurrence 3) Pathologically proven large pleural effusion associated with non-small-cell lung cancer 4) Chemotherapy naive except for EGFR-TKI 5) Age over 20 years old with performance status 0-1 6) No prior pleurodesis 7) No prior thoracotomy nor thoracic radiation within 4 weeks 8) Adequate organ funcions 9) Signed informed consent

Exclusion criteria

Exclusion criteria: 1) Actuve concomitant malignancy 2) Massive pericardial effusion 3) With rain metastasis, or tumor with large vessel invasion or cavity formation 4) Episode of hemoptysis 5) Those judged to be not suitable by the attending physician

Design outcomes

Primary

Measure	Time frame
4-week PPFS rate (Pleural progression-free survival (PPFS) was defined as the time from randomization to the first observation of pleural progression or death due to any cause.)	—

Secondary

Measure	Time frame
Ovrall survival, Progression free survival, Response rate, Time to pleural progression, Safety, Quality of life	—

Countries

Japan

Contacts

Public ContactMadoka Kimura

Shizuoka Cancer Center Division of Thoracic Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026